ES2161768T3
(es)
*
|
1993-06-30 |
2001-12-16 |
Fujisawa Pharmaceutical Co |
Medicamento encapsulado.
|
DE4401646A1
(de)
*
|
1994-01-21 |
1995-07-27 |
Krewel Werke Gmbh |
Optimal freisetzende Kava-Extrakte
|
DE19504832A1
(de)
*
|
1995-02-14 |
1996-08-22 |
Basf Ag |
Feste Wirkstoff-Zubereitungen
|
US5900425A
(en)
*
|
1995-05-02 |
1999-05-04 |
Bayer Aktiengesellschaft |
Pharmaceutical preparations having controlled release of active compound and processes for their preparation
|
DE19515972A1
(de)
*
|
1995-05-02 |
1996-11-07 |
Bayer Ag |
Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
|
SE9502244D0
(sv)
*
|
1995-06-20 |
1995-06-20 |
Bioglan Ab |
A composition and a process for the preparation thereof
|
TW487582B
(en)
*
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
CA2240161C
(en)
|
1996-05-20 |
2005-05-24 |
Janssen Pharmaceutica N.V. |
Antifungal compositions with improved bioavailability
|
AU3358397A
(en)
*
|
1996-07-08 |
1998-02-02 |
Kyowa Hakko Kogyo Co. Ltd. |
Solid dispersions or solid dispersion preparations of tricyclic compounds
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
JPH11130698A
(ja)
*
|
1997-10-31 |
1999-05-18 |
Freunt Ind Co Ltd |
アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
|
IE980115A1
(en)
*
|
1998-02-16 |
2000-02-09 |
Biovail Internat Ltd |
Solubilizing delivery systems and method of manufacture
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
ES2307482T3
(es)
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
ES2398643T3
(es)
*
|
1999-12-23 |
2013-03-20 |
Mayne Pharma International Pty Ltd. |
Composiciones farmacéuticas mejoradas para fármacos escasamente solubles
|
US7115279B2
(en)
*
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US20030099703A1
(en)
*
|
2000-08-11 |
2003-05-29 |
Shigeru Aoki |
Drug-containing solid dispersion having improved solubility
|
KR20020014570A
(ko)
*
|
2000-08-18 |
2002-02-25 |
김충섭 |
고체분산화시킨 무정형 이프리플라본의 제조방법
|
CA2450957A1
(en)
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
WO2003000226A2
(en)
*
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions containing polymer and drug assemblies
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
ES2309294T3
(es)
|
2002-02-01 |
2008-12-16 |
Pfizer Products Inc. |
Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
|
KR20040011248A
(ko)
*
|
2002-07-30 |
2004-02-05 |
환인제약 주식회사 |
암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
|
ES2333318T3
(es)
|
2002-08-12 |
2010-02-19 |
Bend Research, Inc. |
Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
|
JP2003146878A
(ja)
*
|
2002-11-22 |
2003-05-21 |
Sawai Pharmaceutical Co Ltd |
ニルバジピン含有易溶性固形製剤およびその製造法
|
EP1961419B1
(en)
|
2002-12-20 |
2010-03-24 |
Pfizer Products Inc. |
Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
|
JP4783278B2
(ja)
*
|
2003-02-03 |
2011-09-28 |
ノバルティス アーゲー |
医薬製剤
|
ES2334029T3
(es)
*
|
2003-05-15 |
2010-03-04 |
Roskamp Research Llc |
Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis.
|
US20080293801A1
(en)
*
|
2003-11-14 |
2008-11-27 |
Pfizer Inc. |
Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
|
WO2005056542A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Pfizer Inc. |
Compositions comprising an hiv protease inhibitor
|
EP1753766A1
(en)
|
2004-05-25 |
2007-02-21 |
Pfizer Products Inc. |
Tetraazabenzo(e)azulene derivatives and analogs thereof
|
KR20050119397A
(ko)
*
|
2004-06-16 |
2005-12-21 |
보람제약주식회사 |
고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
|
GB0428152D0
(en)
*
|
2004-12-22 |
2005-01-26 |
Novartis Ag |
Organic compounds
|
US8617604B2
(en)
|
2005-02-03 |
2013-12-31 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
JP2006347939A
(ja)
*
|
2005-06-15 |
2006-12-28 |
Tokyo Printing Ink Mfg Co Ltd |
薬物高分子複合体の製造方法及び薬物高分子複合体
|
US10532028B2
(en)
*
|
2005-07-28 |
2020-01-14 |
Isp Investments Llc |
Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
|
CA2631233C
(en)
|
2005-11-28 |
2011-11-08 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
JP2007308480A
(ja)
*
|
2006-04-20 |
2007-11-29 |
Shin Etsu Chem Co Ltd |
腸溶性固体分散体を含んでなる固形製剤
|
JP2007308479A
(ja)
*
|
2006-04-20 |
2007-11-29 |
Shin Etsu Chem Co Ltd |
固体分散体製剤
|
US8343548B2
(en)
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
US8343547B2
(en)
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
PL2526933T3
(pl)
|
2006-09-22 |
2015-08-31 |
Pharmacyclics Llc |
Inhibitory kinazy tyrozynowej Brutona
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
WO2008076780A2
(en)
*
|
2006-12-14 |
2008-06-26 |
Isp Investments Inc. |
Amorphous valsartan and the production thereof
|
US8613946B2
(en)
*
|
2006-12-21 |
2013-12-24 |
Isp Investment Inc. |
Carotenoids of enhanced bioavailability
|
US7638541B2
(en)
*
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
CN101622302B
(zh)
*
|
2007-01-26 |
2013-01-23 |
Isp投资公司 |
生产喷雾干燥产品的制剂工艺方法
|
WO2008092046A2
(en)
*
|
2007-01-26 |
2008-07-31 |
Isp Investments Inc. |
Amorphous oxcarbazepine and the production thereof
|
US20080220029A1
(en)
*
|
2007-03-05 |
2008-09-11 |
Charlene Ng |
Fast-dissolving/disintegrating film preparation having high proportion of active
|
CN101657216B
(zh)
|
2007-04-20 |
2012-11-21 |
大同化成工业株式会社 |
干式固体分散体用基剂、含有该基剂的固体分散体及含有该分散体的组合物
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
WO2008149230A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
|
WO2008149192A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
AU2008279447A1
(en)
|
2007-07-19 |
2009-01-29 |
Metabolex, Inc. |
N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20100093810A1
(en)
*
|
2007-10-05 |
2010-04-15 |
Alzheimer's Institute Of America, Inc. |
Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
|
TWI500422B
(zh)
*
|
2007-10-05 |
2015-09-21 |
Alzheimer S Inst Of America Inc |
以(-)-尼代地平(nilvadipine)對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法
|
US9724362B2
(en)
|
2007-12-06 |
2017-08-08 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
US9233078B2
(en)
|
2007-12-06 |
2016-01-12 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
|
US20090163561A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
CA2719507C
(en)
*
|
2008-03-31 |
2018-03-27 |
Metabolex, Inc. |
Oxymethylene aryl compounds and uses thereof
|
WO2010027875A2
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
US8410127B2
(en)
*
|
2009-10-01 |
2013-04-02 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US20130149346A1
(en)
*
|
2010-03-08 |
2013-06-13 |
ratiopharm GmbH Graf-Arco-Strasse 3 |
Dabigatran etexilate-containing pharmaceutical composition
|
EP2558866B1
(en)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
WO2011139765A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
CA2799708A1
(en)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phenyl benzoylamides
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
EP2609095A4
(en)
|
2010-08-27 |
2014-06-18 |
Calcimedica Inc |
COMPOUNDS MODULATING INTRACELLULAR CALCIUM
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2013192566A1
(en)
|
2012-06-21 |
2013-12-27 |
Mayne Pharma International Pty. Ltd. |
Itraconazole compositions and dosage forms, and methods of using the same
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
BR112016012728A2
(pt)
|
2013-12-05 |
2020-08-11 |
Pharmacyclics Llc |
compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos
|
HUE047319T2
(hu)
|
2014-02-10 |
2020-04-28 |
Respivant Sciences Gmbh |
Hízósejt-stabilizátorral történõ kezelés szisztémás rendellenességekhez
|
AU2015213681B2
(en)
|
2014-02-10 |
2020-03-12 |
Respivant Sciences Gmbh |
Mast cell stabilizers for lung disease treatment
|
CA2942759C
(en)
|
2014-03-17 |
2018-01-09 |
Pfizer Inc. |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
SG11201706989SA
(en)
|
2015-02-27 |
2017-09-28 |
Curtana Pharmaceuticals Inc |
Inhibition of olig2 activity
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
EP3331522A1
(en)
|
2015-08-07 |
2018-06-13 |
Patara Pharma LLC |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
AU2017263574B2
(en)
|
2016-05-12 |
2022-11-17 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
KR20190035752A
(ko)
|
2016-08-03 |
2019-04-03 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
JP7028860B2
(ja)
|
2016-08-26 |
2022-03-02 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
AU2017321495A1
(en)
|
2016-08-31 |
2019-03-21 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
EP3522983A4
(en)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
|
BR112019018688A2
(pt)
|
2017-03-10 |
2020-04-07 |
Pfizer |
derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
|
US11382897B2
(en)
|
2017-11-07 |
2022-07-12 |
The Regents Of The University Of Michigan |
Therapeutic combination for treatment of cerebellar ataxia
|
US11110177B2
(en)
|
2017-11-10 |
2021-09-07 |
The Regents Of The University Of Michigan |
ASH1L degraders and methods of treatment therewith
|
US11324729B2
(en)
|
2017-12-07 |
2022-05-10 |
The Regents Of The University Of Michigan |
NSD family inhibitors and methods of treatment therewith
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
EP4155293B1
(en)
|
2018-06-07 |
2025-07-30 |
The Regents of The University of Michigan |
Prc1 inhibitors and methods of treatment therewith
|
AU2019310118A1
(en)
|
2018-07-27 |
2021-03-11 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic TRPV1 agonists
|
WO2020046466A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology, Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
CR20210110A
(es)
|
2018-08-31 |
2021-05-13 |
Pfizer |
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
|
US12251405B2
(en)
|
2018-10-03 |
2025-03-18 |
Myos Corp. |
Spray dried follistatin product
|
US10925904B2
(en)
|
2018-11-06 |
2021-02-23 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
KR102726437B1
(ko)
|
2018-12-31 |
2024-11-05 |
바이오메아 퓨전, 인크. |
메닌-mll 상호작용의 비가역적 억제제
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
CN114144178A
(zh)
|
2019-03-15 |
2022-03-04 |
尤尼赛夫医疗公司 |
尼可地尔衍生物
|
BR112021020295A2
(pt)
|
2019-04-19 |
2021-12-14 |
Pfizer |
Agentes antiproliferativos para o tratamento de pah
|
CN113874019A
(zh)
|
2019-05-20 |
2021-12-31 |
辉瑞大药厂 |
用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
WO2020261144A1
(en)
|
2019-06-28 |
2020-12-30 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
WO2021040027A1
(ja)
*
|
2019-08-30 |
2021-03-04 |
三栄源エフ・エフ・アイ株式会社 |
非晶質の難水溶性素材を含有する固体組成物、及びその製造方法
|
KR20220054378A
(ko)
*
|
2019-08-30 |
2022-05-02 |
산에이겐 에후.에후. 아이. 가부시키가이샤 |
비정질의 난수용성 소재를 함유하는 고체 조성물 및 그 제조 방법
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
AU2021289169B2
(en)
|
2020-06-09 |
2024-01-04 |
Pfizer Inc. |
Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
|
WO2022010537A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Gas41 inhibitors and methods of use thereof
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3228627A1
(en)
|
2021-08-11 |
2023-02-16 |
Thomas Butler |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
US20240409558A1
(en)
|
2021-09-13 |
2024-12-12 |
Biomea Fusion, Inc. |
Irreversible inhibitors of kras
|
US20250066386A1
(en)
|
2021-11-09 |
2025-02-27 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
CN120641401A
(zh)
|
2022-10-07 |
2025-09-12 |
辉瑞公司 |
Hsd17b13抑制剂和/或降解剂
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
KR20250086775A
(ko)
|
2022-10-18 |
2025-06-13 |
화이자 인코포레이티드 |
파타틴-유사 인산지질분해효소 도메인-함유 단백질 3(pnpla3) 개질제
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024086613A2
(en)
|
2022-10-19 |
2024-04-25 |
Myos Corp. |
Myogenic compounds
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
KR20250117453A
(ko)
|
2022-12-16 |
2025-08-04 |
화이자 인코포레이티드 |
3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도
|
US20250002458A1
(en)
|
2023-05-24 |
2025-01-02 |
Unicycive Therapeutics Inc. |
Salt forms of nicorandil derivative
|
WO2024249950A1
(en)
|
2023-06-02 |
2024-12-05 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20250145571A1
(en)
|
2023-09-26 |
2025-05-08 |
Unicycive Therapeutics, Inc. |
Amino acid prodrugs of nicorandil
|